Selenium Claim Ruling Forces FDA's Hand, May Clear Path For More QHCs
This article was originally published in The Tan Sheet
Executive Summary
A court decision obligating FDA to reconsider a slate of qualified health claims for selenium could compel the agency to allow more QHCs for dietary supplements
You may also be interested in...
Amarin Decision Could Spur Pressure Against FDA On Supplement Claim Policy
First Amendment advocate Jonathan Emord says the industry bows to FDA “intimidation” in not making truthful claims for their products. But the federal district court ruling for Amarin is the latest decision to strike against FDA’s policy on regulating supplement label claims, he says.
Amarin Decision Could Spur Pressure Against FDA On Supplement Claim Policy
First Amendment advocate Jonathan Emord says the industry bows to FDA “intimidation” in not making truthful claims for their products. But the federal district court ruling for Amarin is the latest decision to strike against FDA’s policy on regulating supplement label claims, he says.
Drug Literature Cases Raise First Amendment Issues
Litigation over the dissemination of scientific information at odds with FDA's instructions could define how the right to freedom of speech applies to marketing food and drug products.